Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hitonowa Medical's intranasal stem cell culture supernatant is a cell-free regenerative biologic derived from the conditioned medium of human deciduous (baby) tooth stem cells. This therapeutic product contains a complex mixture of growth factors and cytokines intended to promote neural regeneration and reduce neuroinflammation. By utilizing an intranasal delivery route, the biologic aims to bypass the blood-brain barrier via the olfactory and trigeminal nerve pathways, delivering active factors directly to the central nervous system. It is primarily utilized as a clinical service in Japan for neurological and cognitive conditions, including dementia, stroke sequelae, ALS-related swallowing dysfunction, COVID-19-related brain fog, and depression.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Stem Cell Culture Supernatant (intranasal) - Hitonowa Medical.